Pharmaxis Second Quarter 2023 Earnings: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)
Pharmaxis (ASX:PXS) Second Quarter 2023 Results
Key Financial Results
Revenue: AU$1.05m (down 62% from 2Q 2022).
Net loss: AU$5.82m (loss widened by 3.1% from 2Q 2022).
AU$0.008 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pharmaxis Earnings Insights
Looking ahead, revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Australia.
Performance of the Australian Pharmaceuticals industry.
The company's shares are down 6.8% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Pharmaxis has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
